O	0	5	Phase
O	6	8	II
O	9	14	study
O	15	17	of
B-intervention	18	29	gemcitabine
I-intervention	30	32	in
I-intervention	33	44	combination
I-intervention	45	49	with
I-intervention	50	61	vinorelbine
O	62	68	versus
B-control	69	80	gemcitabine
I-control	81	89	followed
I-control	90	92	by
I-control	93	104	vinorelbine
O	105	108	for
B-eligibility	109	119	metastatic
I-eligibility	120	126	breast
I-eligibility	127	133	cancer
O	133	134	.

O	135	137	No
O	138	143	clear
O	144	148	data
O	149	152	are
O	153	162	available
O	163	173	concerning
O	174	177	the
O	178	189	superiority
O	190	192	of
O	193	204	combination
O	205	217	chemotherapy
O	218	220	to
O	221	231	sequential
O	232	239	therapy
O	240	245	using
O	246	252	agents
O	253	259	beyond
O	260	263	1st
O	264	266	or
O	267	270	2nd
O	271	275	line
O	276	288	chemotherapy
O	289	292	for
O	293	301	treating
O	302	310	patients
O	311	315	with
O	316	326	metastatic
O	327	333	breast
O	334	340	cancer
O	340	341	.

O	342	350	Patients
O	351	355	were
O	356	366	randomized
O	367	369	to
O	370	377	receive
O	378	379	a
O	380	391	combination
O	392	394	of
O	395	406	gemcitabine
O	407	410	and
O	411	422	vinorelbine
O	423	425	or
O	426	437	gemcitabine
O	438	443	until
O	444	451	disease
O	452	463	progression
O	464	472	followed
O	473	475	by
O	476	487	vinorelbine
O	488	499	monotherapy
O	499	500	.

O	501	508	Quality
O	509	511	of
O	512	516	life
O	517	520	was
O	521	529	assessed
O	530	535	using
O	536	541	EORTC
O	542	545	QLQ
O	545	546	-
O	546	549	C30
O	550	564	questionnaires
O	564	565	.

B-intervention-participants	566	571	Forty
I-intervention-participants	571	572	-
I-intervention-participants	572	575	two
O	576	584	patients
O	585	589	were
O	590	600	randomized
O	601	603	to
O	604	607	the
O	608	619	combination
O	620	623	arm
O	624	627	and
B-control-participants	628	630	40
O	631	635	were
O	636	646	randomized
O	647	649	to
O	650	653	the
O	654	664	sequential
O	665	668	arm
O	668	669	.

O	670	678	Baseline
O	679	694	characteristics
O	695	699	were
O	700	704	well
O	705	713	balanced
O	714	721	between
O	722	725	the
O	726	730	arms
O	730	731	.

O	732	735	The
B-outcome	736	742	median
I-outcome	743	749	number
I-outcome	750	752	of
I-outcome	753	765	chemotherapy
I-outcome	766	772	cycles
O	773	776	was
B-iv-cont-median	777	778	4
O	779	780	(
O	780	785	range
O	785	786	,
O	787	788	1
O	788	789	-
O	789	791	23
O	791	792	)
O	793	796	for
O	797	800	the
O	801	812	combination
O	813	816	arm
O	817	820	and
B-cv-cont-median	821	822	6
O	823	824	(
O	824	829	range
O	829	830	,
O	831	832	1
O	832	833	-
O	833	835	25
O	835	836	)
O	837	840	for
O	841	844	the
O	845	855	sequential
O	856	859	arm
O	859	860	.

O	861	869	Patients
O	870	879	receiving
O	880	891	combination
O	892	899	therapy
O	900	903	had
O	904	905	a
O	906	912	higher
B-outcome	913	922	composite
I-outcome	923	931	response
I-outcome	932	936	rate
O	937	938	(
B-iv-bin-percent	938	940	26
I-iv-bin-percent	940	941	.
I-iv-bin-percent	941	942	8
I-iv-bin-percent	942	943	%
O	944	946	vs
O	946	947	.
B-cv-bin-percent	948	950	12
I-cv-bin-percent	950	951	.
I-cv-bin-percent	951	952	5
I-cv-bin-percent	952	953	%
O	953	954	;
O	955	956	P
O	957	958	=
O	959	960	0
O	960	961	.
O	961	964	106
O	964	965	)
O	966	969	but
O	970	971	a
O	972	979	shorter
B-outcome	980	986	median
I-outcome	987	991	time
I-outcome	992	994	to
I-outcome	995	1004	treatment
I-outcome	1005	1012	failure
O	1013	1014	(
B-iv-cont-median	1014	1015	3
I-iv-cont-median	1015	1016	.
I-iv-cont-median	1016	1017	6
O	1018	1020	vs
O	1020	1021	.
B-cv-cont-median	1022	1023	4
I-cv-cont-median	1023	1024	.
I-cv-cont-median	1024	1025	4
I-cv-cont-median	1026	1032	months
O	1032	1033	,
O	1034	1035	P
O	1036	1037	=
O	1038	1039	0
O	1039	1040	.
O	1040	1043	252
O	1043	1044	)
O	1045	1047	as
O	1048	1056	compared
O	1057	1059	to
O	1060	1068	patients
O	1069	1078	receiving
O	1079	1089	sequential
O	1090	1101	monotherapy
O	1101	1102	.

B-outcome	1103	1109	Median
I-outcome	1110	1117	overall
I-outcome	1118	1126	survival
O	1127	1130	for
O	1131	1134	the
O	1135	1146	combination
O	1147	1150	and
O	1151	1161	sequential
O	1162	1166	arms
O	1167	1170	was
B-iv-cont-median	1171	1173	10
I-iv-cont-median	1173	1174	.
I-iv-cont-median	1174	1175	6
I-iv-cont-median	1176	1182	months
O	1183	1186	and
B-cv-cont-median	1187	1188	8
I-cv-cont-median	1188	1189	.
I-cv-cont-median	1189	1190	9
I-cv-cont-median	1191	1197	months
O	1197	1198	,
O	1199	1211	respectively
O	1212	1213	(
O	1213	1214	P
O	1215	1216	=
O	1217	1218	0
O	1218	1219	.
O	1219	1222	436
O	1222	1223	)
O	1223	1224	.

B-outcome	1225	1235	Toxicities
O	1236	1240	were
O	1241	1251	manageable
O	1252	1255	and
O	1256	1263	similar
O	1264	1266	in
O	1267	1271	both
O	1272	1276	arms
O	1276	1277	.

B-outcome	1278	1285	Quality
I-outcome	1286	1288	of
I-outcome	1289	1293	life
O	1294	1306	measurements
O	1307	1309	in
O	1310	1316	global
O	1317	1323	health
O	1323	1324	,
O	1325	1329	role
O	1329	1330	,
O	1331	1334	and
O	1335	1341	social
O	1342	1350	function
O	1351	1355	were
O	1356	1364	superior
O	1365	1367	in
O	1368	1371	the
O	1372	1383	combination
O	1384	1387	arm
O	1388	1389	(
O	1389	1390	P
O	1391	1392	<
O	1393	1394	0
O	1394	1395	.
O	1395	1397	05
O	1397	1398	)
O	1398	1399	.

O	1400	1408	Combined
O	1409	1420	gemcitabine
O	1421	1424	and
O	1425	1436	vinorelbine
O	1437	1444	therapy
O	1445	1452	appears
O	1453	1463	comparable
O	1464	1466	to
O	1467	1477	sequential
O	1478	1489	monotherapy
O	1490	1493	for
O	1494	1501	heavily
O	1502	1512	pretreated
O	1513	1521	patients
O	1522	1526	with
O	1527	1537	metastatic
O	1538	1544	breast
O	1545	1551	cancer
O	1552	1554	as
O	1555	1567	demonstrated
O	1568	1570	by
O	1571	1579	improved
O	1580	1587	quality
O	1588	1590	of
O	1591	1595	life
O	1596	1604	outcomes
O	1605	1609	with
O	1610	1617	similar
O	1618	1629	therapeutic
O	1630	1640	efficacies
O	1641	1644	and
O	1645	1655	incidences
O	1656	1658	of
O	1659	1666	adverse
O	1667	1673	events
O	1673	1674	.
